Vaccine maker Vaxcyte to offer 14 million shares in planned IPO priced at $14 to $16

Vaxcyte Inc. PCVX, set terms for its planned initial public offering on Monday, with plans to offer 14 million shares priced at $14 to $16 each. The company has applied to list on Nasdaq under the ticker symbol “PCVX.” BofA Securities, Jefferies and Evercore ISI are lead underwriters on the deal with Cantor and Needham acting as co-managers. “We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide,” says the prospectus. Proceeds of the deal will be used top fund clinical development and for general corporate purposes.
https://www.marketwatch.com/story/vaccine-maker-vaxcyte-to-offer-14-million-shares-in-planned-ipo-priced-at-14-to-16-each-2020-06-08